Mouse IFN-beta Antibody

Catalog #: MAB82341 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB82341-100
MAB82341-SP

1 Image

All IFN-beta Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse IFN-beta Antibody Summary

Species Reactivity

Mouse

Specificity

Detects Mouse IFN‑ beta in direct ELISAs.

Source

Monoclonal Rat IgG₁ Clone # 944213

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Human embryonic kidney cell HEK293-derived Mouse IFN‑ beta
Ile22-Asn182
Accession # P01575

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

ELISA

This antibody functions as an ELISA detection antibody when paired with Rat Anti-Mouse IFN‑ beta Monoclonal Antibody (Catalog # MAB82342).

This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Mouse IFN-beta DuoSet ELISA Kit (Catalog # DY8234-05) for convenient development of a sandwich ELISA or the Mouse IFN-beta Quantikine ELISA Kit (Catalog # MIFNB0) for a complete optimized ELISA.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

ELISA

View Larger

Mouse IFN‑beta ELISA Standard Curve. Recombinant Mouse IFN‑beta protein was serially diluted 2-fold and captured by Rat Anti-Mouse IFN‑beta Monoclonal Antibody (MAB82342) coated on a Clear Polystyrene Microplate (DY990). Rat Anti-Mouse IFN‑beta Monoclonal Antibody (Catalog # MAB82341) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (DY998) followed by Substrate Solution (DY999) and stopping the enzymatic reaction with Stop Solution (DY994).

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-beta

Interferon beta (IFN-beta ), also known as fibroblast IFN, is a secreted, approximately 22 kDa member of the type I interferon family of molecules (1). Mature mouse IFN-beta shares 75% and 47% amino acid sequence identity with the rat and human proteins, respectively. Fibroblasts are the major producers of IFN-beta, but it can also be produced by dendritic cells, macrophages, and endothelial cells in response to pathogens (2). It is transcriptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3, 4). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), a disease model of human multiple sclerosis (MS) (5). Furthermore, IFN-beta has been shown to suppress the Th17 cell response in both MS and EAE and has commonly been used as a treatment for MS (6-10). IFN-beta can additionally induce the expression of the anti-inflammatory cytokine IL-10 (11).

References

González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.
Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.
Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.
Häcker, H. et al. (2006) Nature 439:204.
Teige, I. et al. (2003) J. Immunol. 170:4776.
Shinohara, M.L. et al. (2008) Immunity 29:68.
Guo, B. et al. (2008) J. Clin. Invest. 118:1680.
Ramgolam, V.S. and S. Markovic-Plese (2010) Endocr. Metab. Immune Disord. Drug Targets 10:161.
Martín-Saavedra, F.M. et al. (2008) Mol. Immunol. 45:4008.
Inoue, M. and M.L. Shinohara (2013) Immunology 139:11.
Wang, H. et al. (2011) J. Immunol 186:675.